ENGN Stock Summary and Trading Ideas (Engene Holdings | NASDAQ:ENGN)

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Engene Holdings trades on the NASDAQ stock market under the symbol ENGN.

As of March 13, 2026, ENGN stock price declined to $7.16 with 789,185 million shares trading.

ENGN has a beta of 0.77, meaning it tends to be less sensitive to market movements. ENGN has a correlation of 0.02 to the broad based SPY ETF.

ENGN has a market cap of $479.61 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ENGN belongs to (by Net Assets): AVSC, BBC.

ENGN has outperformed the market in the last year with a return of +33.8%, while the SPY ETF gained +21.4%. However, in the most recent history, ENGN shares have underperformed the stock market with its stock returning -15.4% in the last 3 month period and -29.2% for the last 2 week period, while SPY has returned -2.6% and -3.5%, respectively.

ENGN support price is $6.90 and resistance is $7.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENGN shares will trade within this expected range on the day.